Patent foramen ovale treatment strategy: an Italian large prospective study

Brunilda Alushi1, Luigi Biasco, Fulvio Orzan

  • 1aDivision of Cardiology, University of Turin, San Giovanni Battista Hospital, Turin, Italy bDivision of Cardiology, Maria Vittoria Hospital, Turin, Italy cDivision of Cardiology, Cardinal Massaia Hospital, Asti, Italy dDepartment of Neuroscience, San Giovanni Battista Hospital, Turin, Italy.

Insights

Percutaneous closure of patent foramen ovale (PFO) is chosen for large shunts, while medical treatment is preferred for multiple stroke risk factors. Older age, prior strokes, and atrial septal aneurysm predict adverse events, not PFO closure itself.

Area of Science:

  • Cardiology
  • Neurology
  • Interventional Cardiology

Background:

  • Patent foramen ovale (PFO) closure for cryptogenic stroke remains controversial.
  • Understanding factors influencing treatment choice and adverse events is crucial.

Purpose of the Study:

  • To evaluate factors associated with treatment strategy (percutaneous closure vs. medical management) in patients with PFO and cryptogenic stroke or TIA.
  • To identify predictors of adverse events in this patient cohort.

Main Methods:

  • Retrospective analysis of 418 patients with PFO and cryptogenic stroke or TIA.
  • Multivariable logistic regression to assess treatment choice determinants and outcome predictors.
  • Outcome defined as a composite of stroke, TIA, or all-cause mortality.

Main Results:

  • Large interatrial right-to-left shunt favored percutaneous PFO closure (OR 4.79).
  • Multiple cerebrovascular accident (CVA) risk factors favored medical treatment (OR 0.15).
  • Older age (>55 years), previous CVAs, and atrial septal aneurysm (ASA) predicted adverse events (P < 0.05).
  • Percutaneous PFO closure did not predict adverse events (OR 1.10, P = 0.81).

Conclusions:

  • Treatment choice for PFO in cryptogenic stroke is influenced by shunt size and CVA risk factors.
  • Older age, prior CVAs, and ASA are independent predictors of adverse outcomes.
  • Percutaneous PFO closure was not found to be an independent predictor of adverse events in this study.
Abstract

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
528
Mitral Regurgitation III: Medical Management01:25

Mitral Regurgitation III: Medical Management

Mitral regurgitation (MR) is characterized by retrograde blood circulation from the left ventricle into the left atrium due to inadequate mitral valve closure. The severity of the condition, symptoms, and underlying cause determine treatment strategies.Monitoring and Pharmacological TreatmentPatients with mild to moderate MR typically do not need immediate intervention but regular monitoring to assess progression and guide treatment. Patients with mild MR should have an echocardiogram every 3-5...
670
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Mitral Stenosis IV: Nursing Management01:27

Mitral Stenosis IV: Nursing Management

A comprehensive nursing assessment is essential for patients with valvular heart disease, which involves any dysfunction of the heart valves that could impact blood flow and overall heart function.Subjective Data Collection:Chief Complaint and Present Illness: Start with the patient's primary concerns, focusing on the onset, duration, and progression of cardiac symptoms such as dyspnea, fatigue, chest pain, and palpitations.Past Medical History: Collect detailed information on any previous...
409
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Mitral Regurgitation IV: Nursing Management01:28

Mitral Regurgitation IV: Nursing Management

Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
593